This cohort study evaluates risk and progression of nonproliferative diabetic retinopathy in patients with type 2 diabetes with empagliflozin vs a dipeptidyl peptidase 4 inhibitor. … [Read more...] about Empagliflozin and the Risk of Retinopathy in Type 2 Diabetes
News
Diabetic Retinopathy—Another Possible Target for SGLT2 Inhibitors?
In this edition of JAMA Ophthalmology, Tesfaye et al report on an observational study that suggests that empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may slow progression of diabetic retinopathy. … [Read more...] about Diabetic Retinopathy—Another Possible Target for SGLT2 Inhibitors?
Error in Text and Table
In the Original Investigation titled “Sterile Intraocular Inflammation Associated With Faricimab,” published online October 10, 2024, there was an incorrect term used in the Introduction and no Snellen equivalent visual acuity provided in the Results and Table. In the Introduction, the word biospecific was corrected to bispecific; in the Results and Table, the Snellen … [Read more...] about Error in Text and Table
Discrimination Within the US Ophthalmology Workforce
This cross-sectional study describes the frequency, nature, and outcomes of discrimination in the workplace experienced by US ophthalmologists and trainees. … [Read more...] about Discrimination Within the US Ophthalmology Workforce
Bilateral improvement in age-related macular degeneration following unilateral Aflibercept injection
The "fellow-eye effect" in anti-vascular endothelial growth factor (anti-VEGF) therapy is a rare phenomenon, particularly with aflibercept. This case report documents the first instance of this effect in Pakis... … [Read more...] about Bilateral improvement in age-related macular degeneration following unilateral Aflibercept injection
Ocular findings in Baraitser–Winter syndrome with a de novo mutation in the ACTG1 gene: a case report
Baraitser–Winter syndrome (BWS) is rare, and no previous reports have described the visual course of patients with this condition. Herein, we report the long-term visual outcomes and ocular features of a 6-yea... … [Read more...] about Ocular findings in Baraitser–Winter syndrome with a de novo mutation in the ACTG1 gene: a case report
Standard surgical approaches have better outcomes in trachomatous trichiasis
December 04, 2024 1 min read Key takeaways: A study explored bilamellar tarsal rotation with 3 mm or 5 mm incision height and posterior lamellar tarsal rotation. Postoperative trichiasis was more likely with the 5 mm approach. Two standard surgical procedures helped treat patients with trachomatous trichiasis, according to a study … [Read more...] about Standard surgical approaches have better outcomes in trachomatous trichiasis
Regener-Eyes launches backflow prevention bottles, recalls products with previous design
December 04, 2024 1 min read Regener-Eyes has launched a new preservative-free, multidose bottle with an improved design to prevent backflow and avoid bacterial contamination, according to a company press release. “Following last week’s discussion with the FDA, we are confident that our new preservative-free bottles meet the standards for backflow prevention for … [Read more...] about Regener-Eyes launches backflow prevention bottles, recalls products with previous design
Part 4: Advice from the experts: Helpful information for current residents
In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.Video Transcript:Editor's note: The below transcript has been lightly edited for clarity.Constance Okeke, MD:The advice that I would give a resident is to take some time and find out what really gets you … [Read more...] about Part 4: Advice from the experts: Helpful information for current residents
Over 300 patients randomized in Ocular Therapeutix’s SOL-1 phase 3 trial for OTX-TKI
More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024. This is the first registrational clinical trial of OTX-TKI in wet age-related macular degeneration (wet AMD) and is on track to report topline data in the fourth quarter of 2025.1Pravin … [Read more...] about Over 300 patients randomized in Ocular Therapeutix’s SOL-1 phase 3 trial for OTX-TKI